65,437 trials
Cystic Fibrosis
Primary: Number of Participants With Treatment-emergent Adverse Events — 278; 176; 85; 61 participants
Autism
Primary: Percent Change of ABC - Irritability Subscale Score — -44.5 percent change in scores
Gingival Recession
Primary: Percentage of Root Coverage — 66; 73 percentage of area covered
HIV Infections
Primary: Number of Subjects Who Had a Decrease in HIV RNA Per Million CD4+ T Cells in the Ileum — 5 participants
Coronary Heart Disease
Primary: High-sensitivity C-reactive Protein — 1.0; 1.0 mg/dl — p=0.22
Leukemia
Primary: Recommended Phase II Dose of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia — 60; 80; NA mg/m^2 QD
Coronary Artery Disease
Primary: Change From Baseline on ex Vivo Leukotriene B4 Synthesis in Whole Blood — -88126; -95703; -122668; -20843 pg/mL — p=<0.001
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS) — -5.3; -3.3; -3.8; -2.2 units on a scale
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 1 Milligram Per Milliliter — 72; 75; 65; 66 Subjects
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL). — 66; 66; 69; 73…
Healthy
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) — 2.62; 2.63 ug/mL
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects Reporting Serious Adverse Events (SAEs) — 109; 33 Subjects
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Antibody Titers for N. Meningitidis Serogroups A(MenA), W-135(MenW-135), C(MenC) and…
Osteoporosis
Primary: Change in Lumbar Spine BMD From Start of Trial Period III Until End of Trial Period III. — 1.002; 0.990 Percentage Change — p=0.010
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects Reporting Serious Adverse Events (SAEs) — 12; 1 Subjects